Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

New treatments have changed the face of managing hemophilia with an inhibitor, columnist Cazandra Campos-MacDonald writes.

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Novo Nordisk has forged a deal with Gensaic, agreeing to pay up to $354 million per target to access technology for the tissue-selective delivery of molecules to cardiometabolic targets inside cells.

NovoCare also lists Novo Nordisk diabetes products as well as the pharma giant’s drugs for growth-related disorders, hemophilia, and hyperoxaluria. “Today, over 55 million people in the U.S ...

Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon. Alhemo (concizumab) recently ...